Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
ContributorsKuse, E. R.; Chetchotisakd, Ploenchan; da Cunha, C. A.; Ruhnke, Markus; Barrios, Carlos; Raghunadharao, Digumarti; Sekhon, J. S.; Freire, Antonio; Ramasubramanian, Venkatasubramanian; Demeyer, Ignace; Nucci, Marcio; Leelarasamee, Amorn; Jacobs, Frederique; Decruyenaere, Johan; Pittet, Didier; Ullmann, A. J.; Ostrosky-Zeichner, Luis; Lortholary, Olivier; Koblinger, Sonja; Diekmann-Berndt, Heike; Cornely, O. A.
Published inLancet, vol. 369, no. 9572, p. 1519-1527
Publication date2007
Abstract
Keywords
- Apache
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Amphotericin B/ therapeutic use
- Antifungal Agents/ therapeutic use
- Candidiasis/complications/ drug therapy/microbiology
- Double-Blind Method
- Echinocandins
- Female
- Humans
- Lipopeptides
- Lipoproteins/ therapeutic use
- Male
- Microbial Sensitivity Tests
- Middle Aged
- Peptides, Cyclic/ therapeutic use
- Treatment Outcome
Affiliation entities
Citation (ISO format)
KUSE, E. R. et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. In: Lancet, 2007, vol. 369, n° 9572, p. 1519–1527. doi: 10.1016/S0140-6736(07)60605-9
Main files (1)
Article
Identifiers
- PID : unige:7396
- DOI : 10.1016/S0140-6736(07)60605-9
- PMID : 17482982
Journal ISSN0140-6736